Zoetis (ZTS) Announces 3Q Beat and Raise Along with PHARMAQ Deal; Guggenheim Reiterates Buy

Zoetis Reports Third Quarter 2015 Results

Delivers 9% Operational Growth in Revenue and 31% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange Third Quarter 2015 Reported Revenue of $1.2 Billion Was Flat Compared to Third Quarter 2014 Third Quarter 2015 Reported Net Income of $189 Million, or $0.38 Per Diluted Share, Increased 14% and 15%, Respectively, Compared to Third Quarter 2014 Third Quarter 2015 Adjusted Net Income1 of $252 Million, or Adjusted Diluted EPS1 of $0.50, Increased 22% Compared to Third Quarter 2014 Updates Full Year 2015 Revenue Guidance to $4.700 - $4.750 Billion and Full Year 2015 Adjusted Diluted... More

Zoetis to Acquire PHARMAQ, the Global Leader in Vaccines and Innovation for Health Products in Aquaculture

Purchase price of $765 million Strengthens core livestock business with industry-leading vaccines and pharmaceuticals for farmed fish, the fastest growing segment of animal health industry Gains late-stage pipeline anticipated to bring several new products to market in the near term Affirms value creation strategy to deploy capital to strengthen the portfolio and support future growth

FLORHAM PARK, N.J.--(BUSINESS WIRE)--... More

Permira Funds to Sell PHARMAQ to Zoetis Inc. for US$765 Million

STOCKHOLM--(BUSINESS WIRE)-- Permira, the global investment firm, announced today that a company backed by the Permira IV fund has entered into a definitive agreement to sell PHARMAQ Holding AS (PHARMAQ or the Company), the worlds leading aquatic health group, to Zoetis Inc. (NYSE: ZTS) for US$765 million on a debt-free basis.

Since being acquired by the Permira funds in 2013, PHARMAQ has continued its international expansion and cemented its position as the global leader in health products focused on the aquaculture industry. With the backing of the Permira funds, PHARMAQ has increased its... More

Zoetis to Acquire PHARMAQ, the Global Leader in Vaccines and Innovation for Health Products in Aquaculture

Purchase price of $765 million Strengthens core livestock business with industry-leading vaccines and pharmaceuticals for farmed fish, the fastest growing segment of animal health industry Gains late-stage pipeline anticipated to bring several new products to market in the near term Affirms value creation strategy to deploy capital to strengthen the portfolio and support future growth

FLORHAM PARK, N.J.--(BUSINESS WIRE)--... More